Skip to main content
L

Not yet reviewed: this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

5-MeO-DiBF

5-MeO-DiBF molecule structure5-MeO-DiBF molecule structure
5-Methoxy-N,N-diisopropylbenzofuranethylamine
5-MeO-DiPBFOpen in Piru
Psychoactive Class
Chemical Class

5-MeO-DiBF is a synthetic benzofuran psychedelic that can also produce stimulating effects. It was sold online as a designer drug and had little documented human use before its 2015 release; a forensic laboratory in Slovenia first definitively identified it in December 2015. Structurally, it is the benzofuran analogue of 5-MeO-DiPT, with oxygen replacing the related compound’s indole nitrogen. Its pharmacology, metabolism, and toxicity remain poorly understood, so harm reduction is advised.

Dosage & Duration

Log in Piru

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~5 mg
Light5-10 mg
Moderate10-15 mg
Strong15-20 mg
Heavy20+ mg

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

Effects vary widely by individual, dose, and context.

Physical

Cognitive

The head space of 5-MeO-DiBF is described by many as one which is both insightful and relatively normal in its thought processes even at moderate to high doses. The total sum of these cognitive components (regardless of the setting) generally includes:

Visual

Geometry

The visual geometry that is present throughout the experience can be described as more similar in appearance to that of 5-MeO-DALT or AMT than that of LSD, 2C-B or 2C-I. It can be comprehensively described as unstructured in its organization, synthetic in geometric style, intricate in complexity, small in size, slow and smooth in motion, colourful in scheme, glossy in colour, equally blurred and sharp in its edges and equally rounded and angular in its corners. It gives off a synthetic feel that is less impressive than most of the "classical" psychedelics at any level. It has yet to be confirmed whether this compound results in either level 8A or level 8B geometry at heavy doses.

Auditory

Forked from Subjective Effect Documentation work byJosie Kins August 2016.

See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Marquis(MQ)
white → orange2 → brown2 → green2 → blue2
Mecke(ME)
white → brown2 → brown3
Mandelin(MD)
yellow2 → brown2 → brown3
Liebermann(LB)
white → black3
Powered by PROtestkit.eu

Pharmacology

Pharmacodynamics

5-MeO-DiBF is thought to act primarily at the 5-HT2 family of serotonin receptors, with likely partial agonist activity at 5-HT2A. It also appears to have relatively greater activity at 5-HT1A than 5-MeO-DiPT, although the contribution of these receptor interactions to its effects remains uncertain.

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

AMTMAOIsPCP

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

AmphetaminesCocaineDXMTramadol

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

2C-T-x compounds2C-x compoundsCannabisDOx compoundsMDMAMescalineNBOMe compoundsPregabalin
Powered by TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance
Tolerance to 5-MeO-DiBF develops almost immediately after ingestion.
Baseline Reset
In the absence of further consumption, tolerance returns to baseline after about 7 days.
Half Tolerance
After ingestion, tolerance takes about 3 days to decrease to half.
Cross Tolerance

Psychedelics (all psychedelics have reduced effects after 5-MeO-DiBF use)

Harm Potential

Addiction & Dependence

Psychological

Higher doses may increase adverse effects, including possible addiction-related concerns, but 5-MeO-DiBF-specific addiction risk has not been characterized.

Toxicity

Lethal Dosage

The exact toxic dose is described as unknown, and recreational toxicity and long-term health effects are said not to have been scientifically studied.

cardiovascular

Increased heart rate is listed among physical effects.

musculoskeletal

Muscle spasms are listed among physical effects.

thermoregulatory

Temperature regulation suppression is listed among physical effects.

Psychosis Risk

Moderate

Psychosis risk is specifically warned for lithium combinations and may be increased by cannabis or stimulant combinations.

Seizure Risk

Moderate

Lithium is warned to significantly increase psychosis and seizure risk, and tramadol may lower the seizure threshold enough for psychedelics to trigger seizures in susceptible people.

History & Culture

Slovenia first notified 5-MeO-DiBF to the EU Early Warning System on 23 December 2015.1

Legality

International

Controlled internationally under the UN Convention on Psychotropic Substances 1971.

By Country

Illegal3
Germany flagGermanyIllegal (analog/blanket ban)
Switzerland flagSwitzerlandIllegal
United Kingdom flagUnited KingdomIllegal (analog/blanket ban)

References

Source Pages

  1. Bluelight: Pellets & higher-dose reports (2016-2023)
  2. Bluelight: Small & Handy 5-MeO-DiBF thread (2015)
  3. Drug Users Bible by Dominic Milton Trott
  4. Drug Users' Bible - 5-MeO-DiBF page
  5. Erowid: Experience Reports - 5-MeO-DiBF
  6. Isomer Design (TiHKAL/PiHKAL)
  7. PsychonautWiki
  8. TripSit Factsheets
  9. Turn-in descriptions of 5-MeO-DiBF pellets (Bluelight user BathSalts, 2016)
  10. Wikimedia media description - forensic ID (2015)
  11. Wikipedia

Citations

  1. EMCDDA–Europol 2015 Annual Report on the implementation of Council Decision 2005/387/JHA. European Monitoring Centre for Drugs and Drug Addiction (2016). https://doi.org/10.2810/9325741
  2. PubChem PUG REST: 5-MeO-DiBF (CID 125276632). pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/125276632/property/IUPACName,MolecularFormula,MolecularWeight,CanonicalSMILES,InChIKey/JSON1
  3. Sechste Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes, BGBl. 2025 I Nr. 292. recht.bund.de (n.d.). https://www.recht.bund.de/bgbl/1/2025/292/regelungstext.pdf?__blob=publicationFile&v=11
  4. Federal Ministry of Health draft and explanatory memorandum, Sixth Regulation Amending the Schedule to the NpSG. bundesgesundheitsministerium.de (n.d.). https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/Gesetze_und_Verordnungen/GuV/N/RefE_6._VO_zur_AEnderung_NpSG_Anlage.pdf1
  5. Deutscher Bundestag Drucksache 18/8579: Entwurf eines Gesetzes zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe. dserver.bundestag.de (n.d.). https://dserver.bundestag.de/btd/18/085/1808579.pdf1
  6. Neue-psychoaktive-Stoffe-Gesetz (NpSG), § 2 Begriffsbestimmungen. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__2.html1
  7. Neue-psychoaktive-Stoffe-Gesetz (NpSG), § 3 Unerlaubter Umgang mit neuen psychoaktiven Stoffen. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__3.html1
  8. Neue-psychoaktive-Stoffe-Gesetz (NpSG), § 4 Strafvorschriften. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__4.html1
  9. Neue-psychoaktive-Stoffe-Gesetz (NpSG), current consolidated text. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/BJNR261510016.html1
  10. Betäubungsmittelverzeichnisverordnung (BetmVV-EDI), Stand am 13. März 2026, Anhang 6, Verzeichnis e. fedlex.data.admin.ch (n.d.). https://fedlex.data.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/2011/363/20260313/de/html/fedlex-data-admin-ch-eli-cc-2011-363-20260313-de-html-3.html1

Further Reading

  1. HighResNPS consensus fragment ions database
  2. PLOS ONE - HR-MS NPS screening (2020)
  3. Reddit: r/researchchemicals discussion (2015)

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed: this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 5-MeO-DiBF article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.